Context Two recent randomized controlled trials (RCTs) reported overall survival benefit of
triplet therapy (androgen receptor axis–targeted therapy agent [ARAT], docetaxel, and …

Context Multiple treatments for metastatic, hormone-sensitive prostate cancer (mHSPC) are
available, but their effects on health-related quality of life (HRQoL) and benefit-harm balance …

Background The most recent overall survival (OS) and adverse event (AE) data have not
been compared for the three guideline-recommended high-risk non-metastatic castration …

Background The current standard of care for the systemic treatment of metastatic hormone
sensitive prostate cancer (mHSPC) includes androgen deprivation therapy (ADT) with either …

Purpose: Four recent first-line clinical trials leveraging immune-oncology agents
demonstrated an overall survival (OS) benefit relative to sunitinib. We aimed to provide …

Prostate cancer is the most dominant male malignancy worldwide. The clinical presentation
of prostate cancer ranges from localized indolent to rapidly progressing lethal metastatic …

Abstract Context Randomized controlled trials (RCTs) have shown that addition of docetaxel
or androgen receptor axis–targeted therapy (ARAT) to androgen deprivation therapy (ADT) …

Objective To investigate characteristics and outcomes of oligometastatic hormone‐sensitive
prostate cancer (mHSPC) patients undergoing metastases‐directed therapy (MDT) with …

Purpose: To conduct a systematic review and network meta-analysis (NMA) to compare the
efficacy of currently available combination therapies in patients with metastatic hormone …

In this systematic review and network meta-analysis (NMA), we aimed to assess the benefits
and harms of third-line (L3) treatments in randomized controlled trials (RCTs) of patients with …